美因基因(06667.HK) : 黃宇峯不再擔任執董兼首席執行官
美因基因(06667.HK)公佈,黃宇峯已根據公司章程細則,經由不少於四分之三人數的董事簽署通知,不再擔任執行董事職務,昨日(17日)生效。董事會亦宣佈,他不再擔任首席執行官職務。不再擔任相關職務旨在讓黃宇峯專注於銷售方面的職務。
公司指,董事會並不知悉他與董事會之間有任何分歧,亦無任何事項須股東及聯交所垂注。董事會亦認爲,他不再擔任董事職務,將不會對營運產生不利影響。
執行董事姜晶將於首席執行官職位空缺期間,承擔首席執行官職責。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.